Axsome Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AXSM research report →
Range $238 – $380
Price Chart
About the company
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression.
- CEO
- Herriot Tabuteau
- IPO
- 2015
- Employees
- 1,346
- HQ
- New York City, NY, US
AI snapshot
Six angles, distilled from the data.
AXSM remains in a damaged intermediate downtrend, trading well below both the 50-day and 200-day moving averages after a sharp multi-month reset from the 52-week high. The stock is still far above the 52-week low, so the setup is more rebound attempt than fresh uptrend.
Street sentiment stays constructive, with a Buy consensus and an average target of $279.25 versus a recent close of $129.36. Recent target cuts from Guggenheim, UBS, Piper Sandler, RBC, Deutsche Bank, and Morgan Stanley show expectations have been trimmed, but the bias remains positive.
The earnings profile is mixed but improving on the latest print, with the company beating EPS estimates in 4 of the last 8 quarters and the most recent quarter topping by 63.8%. Next-year EPS is modeled at $3.647, so shareholders should watch whether revenue growth and margin leverage can narrow losses faster.
Recent insider activity leans bearish on the discretionary side, led by CEO Herriot Tabuteau and COO Mark Jacobson with multiple sales. Most of the other filings are exempt or automatic award-related transactions, but the repeated open-market selling from top executives is the clearest signal.
Profitability is still weak, but revenue is growing and the balance sheet is not strained. Gross margin is 93.2%, revenue grew 51.9% year over year, and the company ended the year with $322.9 million in cash against $241.3 million of debt and $81.6 million in net cash.
AXSM screens as a premium biotech name on growth expectations, not current earnings power. The stock trades at a negative trailing P/E and sits well below the consensus target, while the sector backdrop still rewards companies that can convert strong gross margins into operating leverage.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.80B
- P/E
- -44.43
- Fwd P/E
- 36.76
- PEG
- -1.09
- P/S
- 8.26
- P/B
- 67.62
- EV/EBITDA
- -49.17
- Div Yield
- 0.00%
- Gross Margin
- 93.25%
- Op Margin
- -17.74%
- Net Margin
- -18.18%
- ROE
- -189.73%
- ROIC
- -39.59%
Latest fiscal year · YoY change
- Revenue
- $638.50M+65.5%
- Gross Profit
- $591.02M+67.7%
- Op Income
- $-169,235,000
- Net Income
- $-183,174,000+36.2%
- EPS
- $-3.68+38.6%
- OCF Growth
- +27.3%
- FCF Growth
- +27.0%
- 52W High
- $260.19
- 52W Low
- $123.00
- 50D MA
- $165.57
- 200D MA
- $196.04
- Beta
- 0.60
- RSI (14)
- 33
- Avg Volume
- 864.13K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Axsome posted strong Q3 growth, led by AUVELITY’s accelerating launch in Alzheimer’s agitation and MDD, while margins stayed healthy and the late-stage CNS pipeline continued to advance.· November 2, 2026
- Total revenue was $260 million, up 52% year over year and 19% sequentially; AUVELITY net product sales were $208 million, up 53% year over year, and SUNOSI revenue was $48.2 million, up 47% year over year.
- Net loss improved to $12.9 million, or $0.25 per share, from $47.2 million, or $0.94 per share, a year ago, showing operating leverage as revenue scaled.
- AUVELITY momentum was the main story: total prescriptions were about 302 thousand, up 40% year over year, with especially strong growth in patients 65 and older tied to the Alzheimer’s agitation launch.
- Gross margin stayed in the low to mid-90% range, while gross-to-net improved for AUVELITY to the mid- to high-40% range; management expects only a slight seasonal uptick in Q4.
- Pipeline updates included progress in smoking cessation, ADHD, binge eating disorder, shift work disorder, fibromyalgia, narcolepsy, schizophrenia, and epilepsy, with several key readouts and filings slated for 2027.
Axsome reported third-quarter total revenue of $260 million, up 52% year over year and 19% sequentially. AUVELITY net product sales were $208 million, up 53% year over year and more than 15% sequentially. SUNOSI net product revenue was $48.2 million, up 47% year over year, and SYMBRAVO net product sales were $3.9 million, up 88% year over year. Gross margin remained in the low to mid-90% range. Cost of revenue was $17.8 million versus $11.9 million a year ago, R&D was $50.6 million versus $40.2 million, and SG&A was $203 million versus $150 million. Net loss was $12.9 million, or $0.25 per share, compared with $47.2 million, or $0.94 per share, in the third quarter of 2025. Cash and cash equivalents ended the quarter at approximately $314 million, versus $323 million at year-end 2025. Management did not provide formal Q4 or full-year financial guidance, but said current cash should be sufficient to fund anticipated operations through cash flow positivity.
Herriot Tabuteau said Axsome delivered another robust quarter driven by commercial progress and an industry-leading neuroscience pipeline. He emphasized that the commercial portfolio is growing at scale, with AUVELITY demand strong in both major depressive disorder and Alzheimer’s disease agitation, and said the company is positioned for “multiple waves of innovation” from its 10-program pipeline. His tone was confident and expansionary, repeatedly pointing to momentum now and in 2027, including “substantial further growth” and a strong finish to the year.
Nick Pizzie highlighted the financial leverage in the model: revenue grew 52% year over year while net loss narrowed to $12.9 million despite higher R&D and SG&A. He cited AUVELITY’s gross-to-net in the mid- to high-40% range, SUNOSI and AUVELITY GTN both improving, and gross margin staying in the low to mid-90% range. He also noted that SG&A was essentially flat sequentially because the field-force expansion is now largely in the run rate, and reaffirmed that about $314 million in cash should fund operations through cash flow positivity.
Analysts focused heavily on AUVELITY’s Alzheimer’s agitation launch, asking about sample-to-paid conversion, payer dynamics, Medicare affordability, abandonment, and whether the launch is tracking the right way versus investor expectations. Management said sampling is running at a similar rate to the MDD launch, NBRx growth among sampled HCPs is positive, Medicare access has been good, and there have been no major bottlenecks beyond normal early-launch system updates. On gross-to-net and data capture, Nick Pizzie said Q3 GTN improved to the mid- to high-40% range, should tick up slightly in Q4 because of seasonality/accrual timing, and that IQVIA capture appeared to dip to around 90% partly due to new pharmacies and one chain stopping reporting to a data provider.
The bull case from this call is that AUVELITY appears to be scaling across both indications, with prescriptions up 40% year over year, strong new prescriber adds, and especially rapid growth in the 65+ segment tied to Alzheimer’s agitation. Management also sounded encouraged by access and affordability, saying patients are filling at a high rate and that primary care adoption is still early and growing. Beyond the current launch, the company has multiple near- and medium-term pipeline catalysts across sleep, psychiatry, neurology, and pain.
The main risks discussed were that investor expectations may be higher than the launch trajectory, and management declined to give specific Q4 or 2027 guidance. Gross-to-net is still high and expected to move slightly higher in Q4, while Q3 prescription data capture may have been affected by channel/reporting changes, making the script trend a bit noisy. Several pipeline programs are still years away from readouts or filing, and some major opportunities depend on future trial success and regulatory outcomes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.3%
- Shares Outstanding
- 52.60M
- Float Shares
- 44.37M
of shares held by institutions
542 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.16M | ▼ 15.83K |
| Blackrock, Inc. | 3.45M | ▲ 348.14K |
| Vanguard Capital Management LLC | 2.01M | ▲ 41.98K |
| Vanguard Portfolio Management LLC | 1.97M | ▼ 10.87K |
| Invesco Ltd. | 1.93M | ▲ 258.65K |
| Fmr LLC | 1.44M | ▼ 94.72K |
| Millennium Management LLC | 1.32M | ▲ 766.94K |
| Two Sigma Investments, LP | 1.11M | ▲ 441.42K |
| Geode Capital Management, LLC | 1.01M | ▲ 43.20K |
| Ubs Group AG | 849.77K | ▲ 697.86K |
| State Street Corp | 823.33K | ▲ 37.67K |
| Deep Track Capital, LP | 800.00K | ▲ 100.00K |
Held by 487 ETFs
Biggest fund positions in AXSM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 3, 26 | Jacobson Mark L. | other | 10,000 |
| Sep 3, 26 | Jacobson Mark L. | other | 10,000 |
| Sep 3, 26 | Jacobson Mark L. | sell | 10,000 |
| Aug 5, 26 | TABUTEAU HERRIOT | other | 45,004 |
| Aug 6, 26 | TABUTEAU HERRIOT | other | 4,660 |
| Aug 5, 26 | TABUTEAU HERRIOT | sell | 45,004 |
| Aug 6, 26 | TABUTEAU HERRIOT | sell | 4,660 |
| Aug 5, 26 | TABUTEAU HERRIOT | other | 45,004 |
| Aug 6, 26 | TABUTEAU HERRIOT | other | 4,660 |
| Jul 1, 26 | TABUTEAU HERRIOT | other | 49,666 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AXSM coverage
Recent articles, reports, and earnings notes.

Axsome Therapeutics (AXSM): Growth Is Strong, Valuation Is Tight
Axsome has evolved into a commercial CNS platform with rapid revenue growth, led by Auvelity and a newly expanded Alzheimer’s agitation opportunity. The stock still earns only a Hold as losses, leverage, and a rich valuation limit upside.

Best Biotech Stocks for September 2026: 7 Research Candidates
A seven-stock biotech countdown spans rare-disease developers, CNS specialists, platform collaborations and commercial-stage therapeutic franchises.

Axsome Therapeutics (AXSM): AUVELITY Drives a Premium Growth Story
Axsome has evolved into a commercial CNS growth story, led by AUVELITY’s rapid prescription gains and a newly expanded Alzheimer’s agitation opportunity. The stock looks attractive on execution, but valuation and ongoing losses keep it from being a low-risk idea.
Want a deeper read on AXSM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 19
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer's Agitation Launch
marketbeat.com · Nov 16
Axsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
fool.com · Nov 14
Nasdaq Sell-Off: 2 Stocks to Buy on the Dip and Hold for 5 Years
fool.com · Nov 11
Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge
marketbeat.com · Nov 9
Axsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
seekingalpha.com · Nov 9
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
fool.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 21, 2026 · Live quote · Not investment advice